Gestational Trophoblastic Disease Treatment Market By Treatment Type (Surgical Treatment, Single-Agent Chemotherapy, Multiagent Chemotherapy, Radiation Therapy, Others); By Disease Type (Hydatidiform Mole, Complete Hydatidiform Mole, Partial Hydatidiform Mole, Invasive Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor); By Risk Group (Low-Risk GTN, High-Risk GTN, Recurrent/Resistant GTN); By End User (General and Tertiary Hospitals, Freestanding Specialty Clinics, Dedicated Cancer Treatment Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Gestational Trophoblastic Disease Treatment Market Size, Share & Forecast, 2026–2032

Gestational Trophoblastic Disease Treatment Market: Leading and Fastest-Growing Segments

Segmentation Category	Largest Segment in 2025	2025 Share	2025 Market Value	CAGR, 2026–2032	Fastest-Growing Segment
Treatment Type	Surgical Treatment	36%	USD 284.4 million	4.8%	Others—Immunotherapy and Specialized Interventions
Disease Type	Hydatidiform Mole—Total	44%	USD 347.6 million	5.0%	Epithelioid Trophoblastic Tumor
End User	General and Tertiary Hospitals	55%	USD 434.5 million	5.1%	Dedicated Cancer Treatment Centers
Geography	North America	38%	USD 300.2 million	4.8%	Asia Pacific

 

What Is the Gestational Trophoblastic Disease Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Gestational Trophoblastic Disease Treatment Market was valued at USD 790 million in 2025 and is projected to reach USD 1.16 billion by 2032, expanding at a CAGR of 5.6% during 2026–2032, according to Strategic Market Research.

 

Gestational trophoblastic disease (GTD) covers abnormal placental growths ranging from complete and partial hydatidiform moles to malignant gestational trophoblastic neoplasia (GTN), including invasive mole, choriocarcinoma, placental-site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT). Treatment usually begins with suction evacuation and then narrows according to serial human chorionic gonadotropin (hCG), histology, metastatic spread, and FIGO risk score. NCI reports about 110–120 GTD cases and 2–7 choriocarcinoma cases per 100,000 pregnancies in the United States. Chemotherapy is ultimately required after approximately 15–20% of complete moles but fewer than 5% of partial moles, making post-evacuation progression central to the treated market. [1]

 

NCI’s current list of FDA-approved drugs used for GTD includes dactinomycin, methotrexate sodium, and vinblastine sulfate. Methotrexate disrupts folate-dependent DNA synthesis, while dactinomycin binds DNA and interferes with transcription. Current FIGO guidance places overall survival near 100% for low-risk GTN and about 90% for high-risk disease. In the 2026 Phase I/II TROPHAMET trial, investigational avelumab plus methotrexate produced hCG normalization in 96.2% of 26 evaluable low-risk patients, with no relapse after a median 41 months; comparative validation is still required. Phase II study NCT05139095 is also evaluating camrelizumab plus apatinib with chemotherapy in ultra-high-risk and refractory or relapsed GTN. [2–5]

 

Market scope and methodology note: The market includes active therapeutic expenditure for surgery, systemic medicines, radiotherapy, administration, and related treatment services. Stand-alone diagnostics, routine ultrasound, and hCG surveillance are excluded unless bundled within a treatment episode. Risk groups are analyzed as a GTN-specific clinical-commercial lens, not as a 100% partition of total GTD treatment revenue.

 

Gestational Trophoblastic Disease Treatment Market Key Report Takeaways

Treatment Type

• Surgical Treatment: 36%, USD 284.4 million in 2025, and 4.8% CAGR; suction evacuation anchors molar-pregnancy care.

• Single-Agent Chemotherapy: 27%, USD 213.3 million, and 5.3% CAGR; methotrexate and dactinomycin lead low-risk GTN treatment.

• Multiagent Chemotherapy: 28%, USD 221.2 million, and 6.8% CAGR; EMA-CO concentrates value in high-risk disease.

• Radiation Therapy: 3%, USD 23.7 million, and 4.2% CAGR; use remains selective, mainly for certain metastatic sites.

• Others: 6%, USD 47.4 million, and 7.2% CAGR; immunotherapy and specialized interventions form the fastest-growing treatment segment.

 

Disease Type

• Hydatidiform Mole: 44%, USD 347.6 million, and 5.0% CAGR; this non-additive parent category combines complete and partial moles.

• Complete Hydatidiform Mole: 26%, USD 205.4 million, and 5.3% CAGR; higher GTN conversion increases downstream therapy.

• Partial Hydatidiform Mole: 18%, USD 142.2 million, and 4.5% CAGR; lower progression limits systemic-treatment intensity.

• Invasive Mole: 18%, USD 142.2 million, and 5.4% CAGR; malignant disease generally enters chemotherapy pathways.

• Choriocarcinoma: 25%, USD 197.5 million, and 6.3% CAGR; metastatic assessment and multiagent treatment raise value per patient.

• PSTT and ETT: PSTT held 8%, USD 63.2 million, at 6.6% CAGR; ETT held 5%, USD 39.5 million, at 7.2% CAGR, with surgery important in localized disease.

 

Risk Group — GTN-Specific Clinical Lens

• Low-Risk GTN: The largest treated GTN group, generally managed with single-agent chemotherapy.

• High-Risk GTN: A smaller group with greater drug, infusion, monitoring, and hospital-resource use.

• Recurrent/Resistant GTN: The principal segment for salvage regimens, resistant-focus surgery, and checkpoint inhibitors.

 

End User

• General and Tertiary Hospitals: 55%, USD 434.5 million, and 5.1% CAGR; they capture surgery, staging, infusions, and acute care.

• Freestanding Specialty Clinics: 26%, USD 205.4 million, and 6.0% CAGR; activity centers on outpatient therapy and coordinated follow-up.

• Dedicated Cancer Treatment Centers: 19%, USD 150.1 million, and 6.6% CAGR; complex and resistant cases support faster growth.

 

Geography

• North America: 38%, USD 300.2 million, and 4.8% CAGR.

• Europe: 27%, USD 213.3 million, and 5.2% CAGR.

• Asia Pacific: 24%, USD 189.6 million, and 7.1% CAGR.

• Latin America: 7%, USD 55.3 million, and 6.0% CAGR.

• Middle East & Africa: 4%, USD 31.6 million, and 6.6% CAGR.

 

How Does the GTD Treatment Funnel Convert Diagnosed Cases Into Market Revenue?

Most molar pregnancies do not progress into prolonged systemic treatment. Serial hCG is the commercial gatekeeper: falling values keep patients in surveillance, while plateauing or rising values trigger GTN assessment and therapy. Charing Cross registers around 1,200 women annually but treats approximately 120, illustrating how monitoring volume substantially exceeds hospital-based cancer treatment. [6]

Centralization increases the influence of a small number of expert centers over protocols and purchasing. The 2025 practical guidelines were developed by 53 GTD clinicians from 31 countries and established consensus definitions and minimum criteria for specialist centers. This supports consistent FIGO scoring, hCG interpretation, and escalation while concentrating supplier access in hospital formularies and commissioned services. [7]

The funnel creates a larger procedure-led molar-pregnancy pool and a smaller, more intensive GTN pool. In GTN, combinations of drugs, repeated infusions, laboratory monitoring, supportive care, and metastatic management increase spending per patient. Very high cure rates limit maintenance revenue, so expansion depends on case capture and correct escalation rather than long treatment duration.

 

Which Treatment Modalities Lead the Gestational Trophoblastic Disease Treatment Market?

Surgical treatment accounted for 36%, or USD 284.4 million in 2025, and is forecast to expand at 4.8%. Suction evacuation remains preferred for hydatidiform mole because it clears uterine tissue while usually preserving fertility. Hysterectomy is selective but more important in localized PSTT or ETT, where chemotherapy sensitivity is lower. [1,2]

Single-agent chemotherapy represented 27%, or USD 213.3 million, and is projected to grow at 5.3%. Methotrexate and dactinomycin remain core low-risk treatments. DailyMed confirms dactinomycin for GTN as a single agent or in combination, while methotrexate labels include low- and high-risk dosing. Recordati Rare Diseases participates through Cosmegen, while Pfizer and Hikma supply methotrexate products. Competition centers on availability, institutional contracts, and treatment familiarity. [3,8,9]

Multiagent chemotherapy held 28%, or USD 221.2 million, and has a 6.8% CAGR. EMA-CO combines etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine. Each episode uses several products and closer toxicity monitoring, lifting value per patient. Gentle etoposide-cisplatin induction for ultra-high-risk disease can reduce early deaths before full-dose treatment. [2]

Radiation therapy accounted for 3%, or USD 23.7 million, at a 4.2% CAGR. It remains an adjunct because GTN is highly chemotherapy-sensitive, with its clearest role in selected brain metastases or localized resistant sites. [2]

Other therapies represented 6%, or USD 47.4 million, and are projected to grow at 7.2%. A 2025 meta-analysis of 15 studies found complete sustained remission in 71.59% of published pembrolizumab-treated GTN cases, but evidence mainly came from small cohorts and case reports. Pembrolizumab blocks PD-1 and avelumab blocks PD-L1. NHS England routinely commissions pembrolizumab for drug-resistant GTN, although it lacks a GTN-specific U.S. FDA indication. [4,10,11]

 

Which Disease Subtypes and Care Settings Shape the Gestational Trophoblastic Disease Treatment Market?

Hydatidiform mole accounted for 44%, or USD 347.6 million, at a 5.0% CAGR. Complete mole represented 26%, USD 205.4 million, and 5.3% CAGR; partial mole represented 18%, USD 142.2 million, and 4.5% CAGR. Complete mole’s higher progression risk creates greater downstream chemotherapy exposure. The 44% parent share is not added again to the disease-type total.

Invasive mole held 18%, or USD 142.2 million, at 5.4% CAGR. Choriocarcinoma represented 25%, or USD 197.5 million, at 6.3% CAGR and carries greater staging and metastatic-treatment intensity. PSTT accounted for 8%, USD 63.2 million, at 6.6% CAGR; ETT held 5%, USD 39.5 million, at 7.2% CAGR. Their relative chemoresistance moves localized care toward hysterectomy and complex cases toward specialist multidisciplinary management. [1,2]

General and tertiary hospitals led with 55%, or USD 434.5 million, and a 5.1% CAGR because they provide evacuation, pathology, staging, multiagent infusion, and emergency care. Freestanding specialty clinics held 26%, USD 205.4 million, and a 6.0% CAGR through outpatient therapy and shared follow-up. Dedicated cancer centers accounted for 19%, USD 150.1 million, and a 6.6% CAGR as high-risk and resistant patients migrate toward centers able to coordinate intensive therapy. Categories are mutually exclusive by principal billing and administration site.

 

How Does the Gestational Trophoblastic Disease Treatment Market Differ Across Regions?

North America held 38%, or USD 300.2 million in 2025, and is projected to expand at 4.8%. Leadership reflects higher treatment expenditure per patient, tertiary gynecologic oncology capacity, and access to surgery and injectable medicines. Lower incidence limits volume-led expansion. [1]

Europe accounted for 27%, or USD 213.3 million, and is forecast to grow at 5.2%. Centralized referral is a major advantage. England combines specialist GTD centers with a defined pembrolizumab route for drug-resistant disease, while European academic centers generated the 2026 TROPHAMET evidence. [4,6,10]

Asia Pacific represented 24%, or USD 189.6 million, and has the fastest regional CAGR at 7.1%. Asia has historically reported higher GTD incidence than Europe and North America, although modern studies show declines in parts of the region. Large referral hospitals and Chinese clinical programs support activity in ultra-high-risk and resistant GTN. [5,12]

Latin America held 7%, or USD 55.3 million, and is projected to grow at 6.0%. Brazil’s GTD reference-center network supports centralized follow-up and treatment, and regional investigators have contributed to pembrolizumab evidence. Access outside major centers remains uneven. [11,13]

Middle East & Africa accounted for 4%, or USD 31.6 million, and is projected to expand at 6.6%. Earlier recognition, chemotherapy availability, and referral capacity are central. A Kenyan single-center study of 98 high- or ultra-high-risk patients recorded 31 deaths and treatment delay in 45.9%; it is not region-wide evidence, but it shows how delayed care can produce resource-intensive, poor-outcome treatment. [14]

 

Which Companies and Clinical Programs Are Shaping the Gestational Trophoblastic Disease Treatment Market?

Competition is split between established injectable suppliers and a small immuno-oncology layer. Generic treatment makes portfolio breadth, supply reliability, hospital contracts, and access to multiple EMA-CO components commercially important. Innovation depends on proving that checkpoint inhibitors can overcome resistance or reduce intensive chemotherapy exposure.

Recordati Rare Diseases
Its clearest GTD-linked branded position is Cosmegen. Dactinomycin is FDA-indicated for GTN as a single agent or in combination and participates in low-risk therapy and EMA-CO. [8]

Pfizer
The company supplies methotrexate and leucovorin products used in established pathways. Its role is institutional supply and regimen support rather than a dedicated GTD franchise. [9]

Fresenius Kabi
Its injectable portfolio includes medicines relevant to EMA-CO and salvage treatment, such as methotrexate, etoposide, cyclophosphamide, leucovorin, cisplatin, and vinblastine. Portfolio breadth supports hospital sourcing. [15]

Hikma Pharmaceuticals
Hikma supplies methotrexate injection with current U.S. labeling that includes GTN, competing through presentation, cost, and supply continuity. [3]

Merck & Co.
Keytruda is relevant in specialist resistant-disease use. Pembrolizumab has supportive meta-analytic evidence and NHS commissioning, but no GTN-specific U.S. indication. [10,11]

Merck KGaA/EMD Serono
The company owns BAVENCIO, the anti-PD-L1 antibody evaluated in TROPHAMET. BAVENCIO is approved for other cancers, not GTN. The 2026 results create a differentiated research position, but comparative efficacy, cost, and fertility evidence remain necessary. [4,16]

 

What Is the Strategic Outlook for the Gestational Trophoblastic Disease Treatment Market Through 2032?

The market is positioned to reach USD 1.16 billion by 2032, but patient numbers are limited, courses are finite, and generic cytotoxic medicines cure most patients. Growth will come from more patients reaching correctly risk-adapted care, greater specialist-center treatment, higher intensity in advanced disease, and selective use of premium salvage therapies rather than prolonged maintenance treatment.

Surgery and conventional chemotherapy should remain the foundation. Multiagent chemotherapy will outpace the overall market because it combines several medicines, infusions, monitoring, and supportive services. Resistant and recurrent GTN will remain the main innovation pool, led by pembrolizumab evidence and studies of avelumab or camrelizumab-based combinations.

 

Gestational Trophoblastic Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 790 Million
Revenue Forecast in 2032	USD 1.16 Billion
Overall Growth Rate	CAGR of 5.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Type, By Risk Group, By End User, By Geography
By Treatment Type	Surgical Treatment, Single-Agent Chemotherapy, Multiagent Chemotherapy, Radiation Therapy, Others
By Disease Type	Hydatidiform Mole, Complete Hydatidiform Mole, Partial Hydatidiform Mole, Invasive Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
By Risk Group	Low-Risk GTN, High-Risk GTN, Recurrent/Resistant GTN
By End User	General and Tertiary Hospitals, Freestanding Specialty Clinics, Dedicated Cancer Treatment Centers
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Australia, Japan, South Korea, India, China, Brazil, Mexico, Saudi Arabia, UAE, South Africa, Kenya
Market Drivers	Greater access to risk-adapted treatment, expansion of specialist-center care, higher use of multiagent chemotherapy in advanced disease, improved referral and case capture, and selective adoption of premium salvage therapies
Customization Option	Available upon request